JAMA Oncol: Tislelizumab combined with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer has a significant effect

Lung cancer is the main cause of cancer incidence and death.

sq- NSCLC s The prognosis of patients receiving standard platinum-based chemotherapy in the diagnosis of NSCLC is poor.

Tislelizumab is a monoclonal antibody with high binding affinity to the PD-1 receptor.

Recently, a study introduced the efficacy and safety results of the key phase 3 clinical trial Tislelizumab combined with chemotherapy (RATIONALE 307) for newly treated patients with advanced sq-NSCLC.

This open-label, randomized Phase 3 clinical trial was conducted in 46 locations in China from July 2018 to June 2019, including newly treated patients with histologically confirmed stage IIIB/IV sq-NSCLC.

This open-label, randomized Phase 3 clinical trial was conducted in 46 locations in China from July 2018 to June 2019, including newly treated patients with histologically confirmed stage IIIB/IV sq-NSCLC.

The patient was randomized (1:1:1) to receive the following intravenous injections with a schedule of 21 days: Tislelizumab (200 mg, day 1) plus paclitaxel (175 mg/m ² , day 1) and carboplatin ( Areas where the concentration is lower than 5, day 1) (group a); Tislelizumab plus nab-paclitaxel (100 mg/m ² , days 1, 8 and 15) and carboplatin (group B); paclitaxel and carboplatin (C group).

The primary endpoint is progression-free survival (PFS) as assessed by the independent review committee (IRC).

In total, 355 sq-NSCLC patients (median age, 62 years, 34-74 years; 330 men, 91.

Progression-free survival as assessed by the independent review committee

Progression-free survival as assessed by the independent review committee Progression-free survival as assessed by the independent review committee Progression-free survival as assessed by the independent review committee

In conclusion, in this phase 3 randomized clinical trial, regardless of the expression of PD-L1, for patients with advanced sq NSCLC, the addition of Tislelizumab and IRC to chemotherapy significantly prolonged PFS, higher ORR, and better safety/resistance.

In conclusion, in this phase 3 randomized clinical trial, regardless of the expression of PD-L1, for patients with advanced sq NSCLC, the addition of Tislelizumab and IRC to chemotherapy significantly prolonged PFS, higher ORR, and better safety/resistance.

Wang J, Lu S, Yu X-, et Al Tislelizumab Plus Chemotherapy VS Chemotherapy Alone AS First-Line Treatment for Advanced Squamous Non-the Small-the Cell Lung Cancer.
:A Phase.
3 Randomized Clinical Trial :.
  .
JAMA Oncol  Published Online April 01, 2021.
com/journals/jamaoncology/fullarticle/2777901" target="_blank" rel="noopener">doi:10.
1001/jamaoncol.
2021.
0366com/journals/jamaoncology/fullarticle/2777901" target="_blank" rel="noopener"> doi:10.
1001/jamaoncol.
2021.
0366

leave a message here